Hospital Acquired Pneumonia (HAP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 189 Published: March 31, 2022 Report Code: GMDGDHC22058IDB

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

The Hospital Acquired Pneumonia Drugs in Development market research report provides an in-depth analysis of the Hospital Acquired Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects.

Hospital Acquired Pneumonia Pipeline Drugs Market Targets

The targets of the Hospital Acquired Pneumonia pipeline drugs market are Beta Lactamase, Penicillin Binding Protein, Bacterial Cell Membrane, Lipopolysaccharide, Peptidoglycan, 16S Ribosomal RNA, 23S Ribosomal RNA, Penicillin Binding Protein 2, Staphylococcus aureus Alpha Hemolysin, and Bacterial Cell Wall.

Hospital Acquired Pneumonia Pipeline Drugs Market, By Targets

Hospital Acquired Pneumonia Pipeline Drugs Market, By Targets

For more target insights, download a free report sample

Mechanisms of Action of Hospital Acquired Pneumonia Pipeline Drugs Market

The mechanisms of action of the Hospital Acquired Pneumonia pipeline drugs market are Beta Lactamase Inhibitor, Penicillin Binding Protein Inhibitor, Bacterial Cell Membrane Disruptor, Lipopolysaccharide Inhibitor, Peptidoglycan Inhibitor, 16S Ribosomal RNA Inhibitor, 23S Ribosomal RNA Inhibitor, Penicillin Binding Protein 2 Inhibitor, Staphylococcus aureus Alpha Hemolysin Inhibitor, and Bacterial Cell Wall Disruptor.

Hospital Acquired Pneumonia Pipeline Drugs Market, By Mechanisms of Action

Hospital Acquired Pneumonia Pipeline Drugs Market, By Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Routes of Administration in Hospital Acquired Pneumonia Pipeline Drugs Market

The routes of administration in the Hospital Acquired Pneumonia pipeline drugs market are intravenous, inhalational, oral, topical, intraarticular, intradermal, intravenous drip, nasal, ophthalmic, and vaginal.

Hospital Acquired Pneumonia Pipeline Drugs Market, By Routes of Administration

Hospital Acquired Pneumonia Pipeline Drugs Market, By Routes of Administration

For more routes of administration insights, download a free report sample

Molecule Types in Hospital Acquired Pneumonia Pipeline Drugs Market

The molecule types in the Hospital Acquired Pneumonia pipeline drugs market are small molecule, monoclonal antibody, peptide, biologic, synthetic peptide, cell therapy, polysaccharide, protein, and recombinant enzyme.

Hospital Acquired Pneumonia Pipeline Drugs Market, By Molecule Types

Hospital Acquired Pneumonia Pipeline Drugs Market, By Molecule Types

For more molecule type insights, download a free report sample

Key Hospital Acquired Pneumonia Pipeline Drugs Market Companies

Some of the key companies in the Hospital Acquired Pneumonia pipeline drugs market are Aridis Pharmaceuticals Inc, Helperby Therapeutics Group Ltd, Wockhardt Ltd, Destiny Pharma Plc, Meiji Seika Pharma Co Ltd, Nabriva Therapeutics Plc, Pfizer Inc, Spexis AG, AiCuris AG, and Allecra Therapeutics GmbH.

Hospital Acquired Pneumonia Pipeline Drugs Market, By Key Companies

Hospital Acquired Pneumonia Pipeline Drugs Market, By Key Companies

To know more about key companies, download a free report sample

Market report overview

Targets Beta Lactamase, Penicillin Binding Protein, Bacterial Cell Membrane, Lipopolysaccharide, Peptidoglycan, 16S Ribosomal RNA, 23S Ribosomal RNA, Penicillin Binding Protein 2, Staphylococcus aureus Alpha Hemolysin, and Bacterial Cell Wall
Mechanisms of Action Beta Lactamase Inhibitor, Penicillin Binding Protein Inhibitor, Bacterial Cell Membrane Disruptor, Lipopolysaccharide Inhibitor, Peptidoglycan Inhibitor, 16S Ribosomal RNA Inhibitor, 23S Ribosomal RNA Inhibitor, Penicillin Binding Protein 2 Inhibitor, Staphylococcus aureus Alpha Hemolysin Inhibitor, and Bacterial Cell Wall Disruptor
Routes of Administration Intravenous, Inhalational, Oral, Topical, Intraarticular, Intradermal, Intravenous Drip, Nasal, Ophthalmic, and Vaginal
Molecule Types Small Molecule, Monoclonal Antibody, Peptide, Biologic, Synthetic Peptide, Cell Therapy, Polysaccharide, Protein, and Recombinant Enzyme
Key Companies Aridis Pharmaceuticals Inc, Helperby Therapeutics Group Ltd, Wockhardt Ltd, Destiny Pharma Plc, Meiji Seika Pharma Co Ltd, Nabriva Therapeutics Plc, Pfizer Inc, Spexis AG, AiCuris AG, and Allecra Therapeutics GmbH

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • Reviews of pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • Evaluation of Hospital Acquired Pneumonia (Infectious Disease) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease).

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Hospital Acquired Pneumonia (HAP) (Infectious Disease). Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Key Players

AiCuris AG

Allecra Therapeutics GmbH

Antabio SAS

Aridis Pharmaceuticals Inc

Biolytx Pharmaceuticals Corp

Bioversys AG

Cellular Biomedicine Group Inc

Centauri Therapeutics Ltd

Clarametyx Biosciences Inc

ContraFect Corp

Cumberland Pharmaceuticals Inc

CytaCoat AB

Destiny Pharma Plc

Dong-A Socio Holdings Co Ltd

Eldec Pharmaceuticals Inc

Entasis Therapeutics Holdings Inc

Evotec SE

GangaGen Biotechnologies Pvt Ltd

Helperby Therapeutics Group Ltd

Hoth Therapeutics Inc

Hypo-Stream Ltd

La Jolla Pharmaceutical Company

Meiji Seika Pharma Co Ltd

Merck & Co Inc

Nabriva Therapeutics Plc

Nosopharm SAS

Omnix Medical Ltd

Peptineo

Pfizer Inc

Pherecydes Pharma SA

Phico Therapeutics Ltd

Pulmobiotics SL

Qilu Pharmaceutical Co Ltd

Revagenix Inc

Shionogi & Co Ltd

Spero Therapeutics Inc

Spexis AG

TGV-Inhalonix Inc

Therapeutic Systems Research Laboratories Inc

VenatoRx Pharmaceuticals Inc

Wockhardt Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hospital Acquired Pneumonia (HAP) – Overview

Hospital Acquired Pneumonia (HAP) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hospital Acquired Pneumonia (HAP) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hospital Acquired Pneumonia (HAP) – Companies Involved in Therapeutics Development

AiCuris AG

Allecra Therapeutics GmbH

Antabio SAS

Aridis Pharmaceuticals Inc

Biolytx Pharmaceuticals Corp

Bioversys AG

Cellular Biomedicine Group Inc

Centauri Therapeutics Ltd

Clarametyx Biosciences Inc

ContraFect Corp

Cumberland Pharmaceuticals Inc

CytaCoat AB

Destiny Pharma Plc

Dong-A Socio Holdings Co Ltd

Eldec Pharmaceuticals Inc

Entasis Therapeutics Holdings Inc

Evotec SE

GangaGen Biotechnologies Pvt Ltd

Helperby Therapeutics Group Ltd

Hoth Therapeutics Inc

Hypo-Stream Ltd

La Jolla Pharmaceutical Company

Meiji Seika Pharma Co Ltd

Merck & Co Inc

Nabriva Therapeutics Plc

Nosopharm SAS

Omnix Medical Ltd

Peptineo

Pfizer Inc

Pherecydes Pharma SA

Phico Therapeutics Ltd

Pulmobiotics SL

Qilu Pharmaceutical Co Ltd

Revagenix Inc

Shionogi & Co Ltd

Spero Therapeutics Inc

Spexis AG

TGV-Inhalonix Inc

Therapeutic Systems Research Laboratories Inc

VenatoRx Pharmaceuticals Inc

Wockhardt Ltd

Hospital Acquired Pneumonia (HAP) – Drug Profiles

(AAI-101 + cefepime) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(avibactam + aztreonam) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(avibactam sodium + ceftazidime) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(cefepime + taniborbactam hydrochloride) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(cefepime + zidebactam) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(cilastatin sodium + imipenem + relebactam) – Drug Profile

Product Description

Mechanism Of Action

History of Events

(durlobactam sodium + sulbactam) – Drug Profile

Product Description

Mechanism Of Action

History of Events

ABX-01 – Drug Profile

Product Description

Mechanism Of Action

History of Events

AlloJoin – Drug Profile

Product Description

Mechanism Of Action

History of Events

arbekacin – Drug Profile

Product Description

Mechanism Of Action

History of Events

Biologic for Ventilator Associated Pneumonia – Drug Profile

Product Description

Mechanism Of Action

BP-002 – Drug Profile

Product Description

Mechanism Of Action

History of Events

cefiderocol sulfate tosylate – Drug Profile

Product Description

Mechanism Of Action

History of Events

CF-370 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CMTX-101 – Drug Profile

Product Description

Mechanism Of Action

EBX-004 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ELD-607 – Drug Profile

Product Description

Mechanism Of Action

History of Events

eravacycline dihydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

exeporfinium chloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

FL-058 – Drug Profile

Product Description

Mechanism Of Action

History of Events

fosfomycin disodium – Drug Profile

Product Description

Mechanism Of Action

History of Events

HT-006 – Drug Profile

Product Description

Mechanism Of Action

History of Events

HY-010B3 – Drug Profile

Product Description

Mechanism Of Action

HY-011B4 – Drug Profile

Product Description

Mechanism Of Action

HY-012B5 – Drug Profile

Product Description

Mechanism Of Action

HY-015B12 – Drug Profile

Product Description

Mechanism Of Action

lefamulin acetate – Drug Profile

Product Description

Mechanism Of Action

History of Events

levonadifloxacin – Drug Profile

Product Description

Mechanism Of Action

MEMANT-3310 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Mul-1867 – Drug Profile

Product Description

Mechanism Of Action

History of Events

murepavadin – Drug Profile

Product Description

Mechanism Of Action

History of Events

nacubactam – Drug Profile

Product Description

Mechanism Of Action

History of Events

NOSO-2G – Drug Profile

Product Description

Mechanism Of Action

History of Events

OMN-6 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Panaecin – Drug Profile

Product Description

Mechanism Of Action

History of Events

panobacumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

Peptides for Complicated Skin and Skin Structure Infections and Hospital Acquired Pneumonia (HAP) – Drug Profile

Product Description

Mechanism Of Action

History of Events

PP-1231 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Proteins to Inhibit Peptidoglycan (Murein) for Bacterial Infections, Cystic Fibrosis, Hospital Acquired Pneumonia and Diabetic Foot Infection – Drug Profile

Product Description

Mechanism Of Action

History of Events

Qn-2251 – Drug Profile

Product Description

Mechanism Of Action

rifabutin – Drug Profile

Product Description

Mechanism Of Action

History of Events

SASPjectPT-3.9 – Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Bacterial Infections – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Hospital Acquired Pneumonia (HAP) and Ventilator Associated Pneumonia (VAP) – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Hospital-Acquired Pneumonia, Intra-Abdominal and Urinary Tract Infections – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Infectious Diseases – Drug Profile

Product Description

Mechanism Of Action

sodium hypochlorite – Drug Profile

Product Description

Mechanism Of Action

SPR-206 – Drug Profile

Product Description

Mechanism Of Action

History of Events

suvratoxumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

tedizolid phosphate – Drug Profile

Product Description

Mechanism Of Action

History of Events

telavancin hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

tosatoxumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

XF-70 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Hospital Acquired Pneumonia (HAP) – Dormant Projects

Hospital Acquired Pneumonia (HAP) – Discontinued Products

Hospital Acquired Pneumonia (HAP) – Product Development Milestones

Featured News & Press Releases

Aug 17, 2021: Venatorx Pharmaceuticals provides update on Cefepime-Taniborbactam

Jun 07, 2021: The results of a preclinical trial demonstrating the benefits of inhaled Pherecydes Pharma phages in treating ventilation-associated pneumonia have been published in the prestigious British Journal of Pharmacology

Apr 19, 2021: Phico Therapeutics awarded up to $18.2 million USD CARB-X funding to advance SASPject antibacterial therapy through phase 1 clinical trials

Apr 19, 2021: Phico Therapeutics awarded up to $18.2 million USD CARB-X funding to advance SASPject antibacterial therapy through phase 1 clinical trials

Oct 16, 2020: CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Recarbrio

Oct 16, 2020: CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Recarbrio

Sep 18, 2020: AstraZeneca receives CHMP positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Zavicefta

Sep 18, 2020: AstraZeneca receives CHMP positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Zavicefta

Jun 25, 2020: CHMP recommended extensions of indication for Zavicefta

Jun 25, 2020: CHMP recommended extensions of indication for Zavicefta

Jun 04, 2020: FDA approves antibiotic to treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Jun 04, 2020: FDA approves antibiotic to treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Jun 01, 2020: FDA accepts Shionogi’s Supplemental New Drug Application with Priority Review for FETROJA (cefiderocol) for the Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia

May 06, 2020: Antabio receives FDA qualified infectious disease product (QIDP) designation for MEM-ANT3310, a novel broad-spectrum combination therapy targeting WHO’s priority pathogens

May 06, 2020: Antabio receives FDA qualified infectious disease product (QIDP) designation for MEM-ANT3310, a novel broad-spectrum combination therapy targeting WHO’s priority pathogens

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hospital Acquired Pneumonia (HAP), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by AiCuris AG, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Allecra Therapeutics GmbH, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Antabio SAS, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Aridis Pharmaceuticals Inc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Biolytx Pharmaceuticals Corp, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Bioversys AG, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Cellular Biomedicine Group Inc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Centauri Therapeutics Ltd, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Clarametyx Biosciences Inc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by ContraFect Corp, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Cumberland Pharmaceuticals Inc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by CytaCoat AB, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Destiny Pharma Plc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Dong-A Socio Holdings Co Ltd, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Eldec Pharmaceuticals Inc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Entasis Therapeutics Holdings Inc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Evotec SE, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by GangaGen Biotechnologies Pvt Ltd, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Helperby Therapeutics Group Ltd, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Hoth Therapeutics Inc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Hypo-Stream Ltd, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by La Jolla Pharmaceutical Company, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Meiji Seika Pharma Co Ltd, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Merck & Co Inc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Nabriva Therapeutics Plc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Nosopharm SAS, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Omnix Medical Ltd, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Peptineo, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Pfizer Inc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Pherecydes Pharma SA, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Phico Therapeutics Ltd, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Pulmobiotics SL, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Qilu Pharmaceutical Co Ltd, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Revagenix Inc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Shionogi & Co Ltd, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Spero Therapeutics Inc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Spexis AG, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by TGV-Inhalonix Inc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Therapeutic Systems Research Laboratories Inc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by VenatoRx Pharmaceuticals Inc, 2022

Hospital Acquired Pneumonia (HAP) – Pipeline by Wockhardt Ltd, 2022

Hospital Acquired Pneumonia (HAP) – Dormant Projects, 2022

Hospital Acquired Pneumonia (HAP) – Dormant Projects, 2022 (Contd..1)

Hospital Acquired Pneumonia (HAP) – Dormant Projects, 2022 (Contd..2)

Hospital Acquired Pneumonia (HAP) – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Hospital Acquired Pneumonia (HAP), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.